How ICER’s Missteps Leave Access in Doubt For Atopic Dermatitis Patients

The Institute for Clinical and Economic Review finds new treatments for atopic dermatitis to be cost effective – justifying health plan coverage for the medications. But methodological missteps invite questions about how secure patients’ access to the treatments will be.

View the Graphic


Categorized in: